• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.

作者信息

Rizzo Alessandro, Ricci Angela Dalia, Brandi Giovanni

机构信息

Department of Experimental, Diagnostic & Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, 40138, Italy.

出版信息

Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.

DOI:10.2217/fon-2020-0986
PMID:33508960
Abstract
摘要

相似文献

1
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.晚期肝细胞癌的免疫联合治疗：塑造一线治疗方向
Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.
2
Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.肝癌患者一线免疫检查点抑制剂治疗之外。
Front Immunol. 2021 Mar 15;12:652007. doi: 10.3389/fimmu.2021.652007. eCollection 2021.
3
Pursuing efficacious systemic therapy for hepatocellular carcinoma.寻求针对肝细胞癌的有效全身治疗方法。
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96. doi: 10.1038/s41575-020-00405-1.
4
Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.二线阿替利珠单抗和贝伐珠单抗治疗对纳武利尤单抗进展后的晚期肝细胞癌的有利反应：克服检查点抑制耐药性的案例报告表明抗血管生成治疗有效。
Medicine (Baltimore). 2021 Jun 25;100(25):e26471. doi: 10.1097/MD.0000000000026471.
5
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.免疫检查点抑制剂治疗肝细胞癌的临床试验启示。
Front Immunol. 2021 Mar 30;12:652172. doi: 10.3389/fimmu.2021.652172. eCollection 2021.
6
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).基于证据的肝细胞癌管理：系统评价和随机对照试验的荟萃分析 (2002-2020)。
Gastroenterology. 2021 Sep;161(3):879-898. doi: 10.1053/j.gastro.2021.06.008. Epub 2021 Jun 12.
7
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.提高免疫疗法治疗肝细胞癌抗肿瘤效果的策略。
Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.
8
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.肝细胞癌免疫治疗新辅助应用的前景
Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.
9
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
10
Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.免疫肿瘤学治疗肝细胞癌：现状与未来。
Clin Liver Dis. 2020 Nov;24(4):739-753. doi: 10.1016/j.cld.2020.07.007. Epub 2020 Sep 2.

引用本文的文献

1
Integrating Bulk and Single-Cell RNA Sequencing Data Reveals the Prognostic Significance of HOXC9-Related Immune Gene Signatures in Hepatocellular Carcinoma.整合批量和单细胞RNA测序数据揭示HOXC9相关免疫基因特征在肝细胞癌中的预后意义
Onco Targets Ther. 2025 Mar 29;18:453-465. doi: 10.2147/OTT.S509625. eCollection 2025.
2
Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate.免疫激活的、高表达PD-1表型在肝细胞癌中与较低的复发率相关。
Pathobiology. 2025;92(3):157-168. doi: 10.1159/000543933. Epub 2025 Mar 4.
3
Unraveling the therapeutic potential of Calculus Bovis in liver cancer: A novel step for targeted cancer treatment.
揭示牛黄在肝癌治疗中的潜在疗效：靶向癌症治疗的新进展。
World J Gastroenterol. 2025 Jan 21;31(3):99358. doi: 10.3748/wjg.v31.i3.99358.
4
Transarterial Chemoembolization Combined with Microwave Ablation in Elderly Patients with Recurrent Medium or Large Hepatocellular Carcinoma.经动脉化疗栓塞联合微波消融治疗老年复发性中、大型肝细胞癌
J Hepatocell Carcinoma. 2024 Oct 22;11:2005-2017. doi: 10.2147/JHC.S455411. eCollection 2024.
5
Advancements in nutritional diagnosis and support strategies during the perioperative period for patients with liver cancer.肝癌患者围手术期营养诊断与支持策略的进展
World J Gastrointest Surg. 2024 Aug 27;16(8):2409-2425. doi: 10.4240/wjgs.v16.i8.2409.
6
Feasibility and Safety of the Clinical Outcomes of TACE Combined with Lenvatinib and PD-1 Blockades in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Exploratory Study.经动脉化疗栓塞术联合乐伐替尼及程序性死亡受体 1 阻断剂治疗门静脉癌栓型肝细胞癌的临床疗效的可行性与安全性：一项回顾性探索性研究
Int J Gen Med. 2024 Aug 21;17:3627-3640. doi: 10.2147/IJGM.S473676. eCollection 2024.
7
Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.二线治疗晚期肝细胞癌的疗效和安全性：一项随机对照试验的网络荟萃分析。
BMC Cancer. 2024 Aug 19;24(1):1023. doi: 10.1186/s12885-024-12780-y.
8
inhibits M2 tumor-associated macrophage polarization Wnt/β-catenin pathway modulation to suppress liver cancer.抑制 M2 肿瘤相关巨噬细胞极化，调节 Wnt/β-catenin 通路，抑制肝癌。
World J Gastroenterol. 2024 Aug 7;30(29):3511-3533. doi: 10.3748/wjg.v30.i29.3511.
9
Optimizing the resveratrol fragments for novel in silico hepatocellular carcinoma de novo drug design.优化白藜芦醇片段，用于新型计算机辅助肝细胞癌从头药物设计。
Sci Rep. 2024 Jul 28;14(1):17336. doi: 10.1038/s41598-024-68403-w.
10
Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.靶向 N4-乙酰胞苷通过抑制 eEF2 介导的 HMGB2 mRNA 翻译抑制肝细胞癌进展。
Cancer Commun (Lond). 2024 Sep;44(9):1018-1041. doi: 10.1002/cac2.12595. Epub 2024 Jul 19.